Hormonal
Semaglutide (2.4 mg once-weekly) produces significant, sustained weight loss (10-15%) and improves cardiometabolic markers in non-diabetic individuals with obesity or overweight, primarily by mimicking GLP-1 to reduce appetite and energy intake.
If you have obesity or are overweight without diabetes, semaglutide (2.4 mg weekly) is a highly effective medical treatment that can help you lose 10-15% of your body weight and improve your metabolic health. It works by reducing your appetite. While it can cause temporary stomach issues like nausea, these often subside. It works best when combined with diet and exercise, but it is significantly more effective than lifestyle changes alone for substantial weight loss.
By activating GLP-1 receptors in the brain, semaglutide helps to decrease appetite, increase feelings of fullness, and reduce food intake, ultimately leading to weight loss... participants receiving semaglutide demonstrated significant weight loss compared to those on placebo or other anti-obesity medications. The magnitude of weight loss varied across studies, 13 of 16 with some reporting an average reduction of 10%-15% of body weight over a treatment period of 68 weeks.
Why this rating
Based on a systematic review of multiple RCTs and meta-analyses, though the paper itself is a review and not a primary trial.
Source
Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes
Mokhlef Alanazi et al. · Cureus · 2024
DOI 10.7759/cureus.67889
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →